Wuhan Zhongcheng Health Bio-Pharm Technology Co. Ltd. has divulged naphthyridine derivatives acting as ATR kinase inhibitors reported to be useful for the treatment of cancer, psoriasis, keloids and benign prostatic hyperplasia.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Terns Pharmaceuticals Inc. has synthesized glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity and liver diseases.
Seinda Pharmaceutical Corp. has disclosed peptides reported to be useful for the treatment of corneal epithelial defect, corneal neovascularization and dry eye.
Debiopharm SA has entered into an exclusive option and license agreement with Sunrock Biopharma SL to advance the development of specifically targeted antibodies.
Krystal Biotech Inc. has received IND clearance from the FDA for KB-408 for the treatment of α1-antitrypsin deficiency (AATD). KB-408 is a modified, replication-defective, nonintegrating HSV-1-derived vector carrying two full-length copies of the serpin family A member 1 gene (SERPINA1) to enable expression of α1-antitrypsin (AAT).
Researchers from Uppsala University and Tomsk Polytechnic University have detailed the discovery and preclinical evaluation of [177Lu]BQ-7876, a novel prostate-specific membrane antigen (PSMA)-targeting therapeutic for the treatment of prostate cancer.
Researchers from Bengbu Medical College have discovered new derivatives of honokiol, a biphenyl neolignan extracted from Magnolia species, which has been shown to possess pharmacological properties, including anticancer, anti-inflammatory, antioxidant, anti-infectious and neuroprotective activities. A total of 21 new honokiol derivatives were synthesized, with derivative [I] being selected as the lead with the most potent in vitro cytotoxic activity.
Via Nova Therapeutics Inc. has received clearance of its IND application from the FDA for its influenza A nucleoprotein inhibitor, VNT-101. The novel investigational small molecule is directed against a novel target, the influenza A nucleoprotein, and is being developed for treatment of seasonal influenza A infection.
RSS
